On October 1, 2018 Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, reported that it will participate in the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 in New York (Press release, Keryx Biopharmaceuticals, OCT 1, 2018, View Source/news-releases/news-release-details/keryx-biopharmaceuticals-announces-participation-upcoming-2" target="_blank" title="View Source/news-releases/news-release-details/keryx-biopharmaceuticals-announces-participation-upcoming-2" rel="nofollow">View Source [SID1234529682]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the conference, Keryx will be participating in a 25 minute panel discussion titled Renal Anemia on Tuesday, October 2, 2018 at 3:30 p.m. Eastern time at the Sofitel New York in New York City.

A live audio webcast of both the panel discussion will be accessible from Keryx’s website at View Source within the Investor Relations section under "events and presentations." An archived version of the webcast will be available for at least 15 days following the conclusion of the panel discussion.